Holen Sie sich die Stockscreener-App
17.22
5.07%
-0.92
Puretech Health Plc Adr Aktie (PRTC) Neueste Nachrichten
PureTech Health H2 Earnings Call Highlights - Yahoo Finance
PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
[20-F] PureTech Health plc Files Annual Report (Foreign Issuer) | PRTC SEC FilingForm 20-F - Stock Titan
Earnings call transcript: PureTech Health’s mixed FY2025 results spark stock drop - Investing.com India
PureTech Health (PRTC) ends Nasdaq ADS listing, focuses trading on LSE - Stock Titan
PureTech to Exit Nasdaq Listing and Consolidise Trading in London - Yahoo Finance UK
PureTech Health to delist ADSs from Nasdaq, focus on LSE By Investing.com - Investing.com South Africa
PureTech Health to delist ADSs from Nasdaq, focus on LSE - Investing.com
PureTech Announces Annual Results for Year Ended December 31, 2025 - ChartMill
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange - Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - ChartMill
PureTech Health (PRTC) Expected to Announce Earnings on Wednesday - MarketBeat
PRTC.L Technical Analysis | Trend, Signals & Chart Patterns | PURETECH HEALTH PLC (LON:PRTC) - ChartMill
0VQ.DE Stock Price, Quote & Chart | PURETECH HEALTH PLC (FRA:0VQ) - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 30.8% in March - MarketBeat
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers - ChartMill
PureTech publishes phase 2b deupirfenidone IPF trial results - Investing.com
PRTC Stock Price, Quote & Chart | PURETECH HEALTH PLCADR (NASDAQ:PRTC) - ChartMill
Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8% - MarketBeat
Short Interest in Citizens Bancorp of Virginia, Inc. (OTCMKTS:CZBT) Grows By 141.4% - Defense World
Pacer American Energy Independence ETF (NYSEARCA:USAI) Sees Large Increase in Short Interest - Defense World
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - ChartMill
Lansdowne Partners UK LLP Takes Position in PureTech Health PLC Sponsored ADR $PRTC - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 36.2% in February - MarketBeat
PureTech Health in the FTSE landscape as technical momentum shifts - Kalkine Media
PureTech to Present at the Leerink Partners Global Healthcare Conference - ChartMill
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Update - MarketBeat
PureTech Health (NASDAQ:PRTC) Shares Up 2%Here's Why - MarketBeat
PRTC Stock Price and Chart — NASDAQ:PRTC - TradingView — Track All Markets
PureTech Health (NASDAQ:PRTC) Trading Up 5.7%Here's Why - MarketBeat
PureTech Health (NASDAQ:PRTC) Trading Up 5.7% – Here’s Why - Defense World
PureTech CEO to present at J.P. Morgan Healthcare Conference By Investing.com - Investing.com India
PureTech CEO to present at J.P. Morgan Healthcare Conference - Investing.com
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
PureTech Health plc (OTCMKTS:PTCHF) Sees Significant Decrease in Short Interest - Defense World
PureTech Health appoints Robert Lyne as permanent CEO By Investing.com - Investing.com UK
PureTech Health appoints Robert Lyne as permanent CEO - Investing.com
PureTech Health (NASDAQ:PRTC) Trading Down 0.7% – Time to Sell? - Defense World
PureTech Health (NASDAQ:PRTC) Trading Down 0.7%Time to Sell? - MarketBeat
PureTech provides update on AGM results following shareholder concerns - Investing.com
PureTech stock falls after FDA meeting on IPF drug - Investing.com
PureTech Health (NASDAQ:PRTC) Trading 0.4% HigherStill a Buy? - MarketBeat
PureTech Health (NASDAQ:PRTC) Stock Price Up 3.1%Time to Buy? - MarketBeat
PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 100.0% in September - MarketBeat
PureTech Health Sees Strong Market Presence in FTSE All Share - Kalkine Media
What Makes PureTech Health (PRTC) a New Buy Stock - Yahoo Finance
BioHarvest Sciences (BHST) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
PureTech launches new entity to advance IPF treatment deupirfenidone - Investing.com
PureTech Health to report half-yearly results on August 28 - Investing.com
PureTech Health announces board leadership transition - Investing.com
PureTech Health announces RSU vesting and share transactions by PDMR - Investing.com
Citius Oncology (CTOR) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Nordic Capital XI ends pursuit of PureTech acquisition - Investing.com
PureTech Health (LSE: PRTC) Presents Promising Phase 1b Data for LYT-200 in AML and MDS at ASH 2024 - Kalkine Media
India Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Argentina Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Norway Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Sweden Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
Mexico Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Asia Pacific Peanut Allergy Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Anti-obesity Medication Market Size & Outlook, 2030 - Grand View Research
PureTech Health (PRTC) Stock Forecast and Price Target 2026 $PRTC - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):